## **Resource Summary Report**

Generated by dkNET on Apr 16, 2025

# <u>Vivli</u>

RRID:SCR\_018080

Type: Tool

## **Proper Citation**

Vivli (RRID:SCR\_018080)

#### Resource Information

URL: https://vivli.org/

Proper Citation: Vivli (RRID:SCR\_018080)

**Description:** Independent, non-profit organization that has developed global data-sharing and analytics platform to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through creation and implementation of sustainable global data-sharing enterprise. Our focus is on sharing individual participant-level data from completed clinical trials. Users can search listed studies, request data sets from data contributors, aggregate data, or share data of their own. Vivli (Center for Clinical Research Data) is launching a portal to share participant-level data from COVID trials.

**Resource Type:** data or information resource, service resource, data repository, organization portal, portal, storage service resource

**Keywords:** Global data sharing, clinical research data, data, sharing, analytical platform, clinical trial, COVID-19-related trials

Related Condition: COVID-19

**Funding:** Doris Duke Charitable Foundation; Leona M. and Harry B. Helmsley Charitable Trust;

Lyda Hill Philanthropies;

Phrma

**Availability:** Restricted

Resource Name: Vivli

Resource ID: SCR\_018080

Alternate IDs: DOI:10.17616/R3SB9S, DOI:10.25504/FAIRsharing.uovQrT, DOI:10.25934

**Alternate URLs:** https://vivli.org/vivli-covid-19-portal-2/, https://doi.org/10.17616/R3SB9S, https://doi.org/10.17616/r3sb9s, https://doi.org/10.25934/, https://dx.doi.org/10.25934/, https://fairsharing.org/10.25504/FAIRsharing.uovQrT

**Record Creation Time:** 20220129T080338+0000

Record Last Update: 20250416T063834+0000

## Ratings and Alerts

No rating or validation information has been found for Vivli.

No alerts have been found for Vivli.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We found 1139 mentions in open access literature.

**Listed below are recent publications.** The full list is available at <u>dkNET</u>.

Labauge P, et al. (2025) TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program. Neurology and therapy, 14(1), 177.

De Block C, et al. (2025) Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes therapy: research, treatment and education of diabetes and related disorders, 16(1), 43.

Jacobs JS, et al. (2025) Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps. Advances in therapy, 42(1), 510.

Sindher SB, et al. (2025) Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study. Allergy, 80(1), 227.

Lugogo NL, et al. (2025) Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry. Advances in therapy, 42(2), 849.

Dam T, et al. (2025) A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance. Nature communications, 16(1), 414.

Wuyts WA, et al. (2025) Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON. Lung, 203(1), 25.

Chalmers JD, et al. (2025) Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study. The European respiratory journal, 65(1).

Gudzune KA, et al. (2025) Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study. Diabetes, obesity & metabolism, 27(2), 539.

Klamroth R, et al. (2025) Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors. Advances in therapy, 42(1), 427.

Liu YL, et al. (2025) Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. Cancer, 131(2), e35707.

Naik H, et al. (2025) Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study. Molecular genetics and metabolism reports, 42, 101174.

Ding H, et al. (2025) Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy. NPJ precision oncology, 9(1), 5.

Kim G, et al. (2025) Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis. Advances in therapy, 42(2), 918.

Abegesah A, et al. (2025) Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 95(1), 23.

Lebwohl M, et al. (2025) Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events. Dermatology and therapy, 15(1), 161.

Álvarez Román MT, et al. (2025) Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors. Advances in therapy, 42(1), 442.

le Roux CW, et al. (2025) Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor

dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial. Diabetes, obesity & metabolism, 27(2), 993.

Mao-Draayer Y, et al. (2025) Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Advances in therapy, 42(1), 395.

Shapiro RE, et al. (2025) Factors and Reasons Associated with Hesitating to Seek Care for Migraine: Results of the OVERCOME (US) Study. Neurology and therapy, 14(1), 135.